Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

As­traZeneca and Dai­ichi Sankyo are chang­ing the ap­proval sub­mis­sion strat­e­gy for its planned En­her­tu suc­ces­sor, datopotam­ab derux­te­can (Da­to-DXd), af­ter a few missed tri­als.

The com­pa­nies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER